RecruitingNot ApplicableNCT05710211

Clonal Architecture of ASXL1-mutated Myelofibrosis

Sponsor

University Hospital, Angers

Enrollment

50 participants

Start Date

Apr 24, 2023

Study Type

INTERVENTIONAL

Conditions

Myelofibrosis

Summary

Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Clonal architecture determination for people with myelofibrosis. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALClonal architecture determination

Biological: * Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing * Secondary outcome: transcriptomic study by RNA-sequencing

Locations(13)

CHU Angers

Angers, France

CHRU Brest

Brest, France

CH Cholet

Cholet, France

CHU Henri MONDOR

Créteil, France

Institut Paoli Calmettes

Marseille, France

CHU Nantes

Nantes, France

AP-HP Hôpital Saint Louis

Paris, France

Hôpital Bicêtre

Paris, France

CHU de Bordeaux

Pessac, France

CHU Lyon

Pierre-Bénite, France

CH de Cornouaille

Quimper, France

CHRU Tours - Hôpital Bretonneau

Tours, France

CH de Vannes

Vannes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05710211

Related Trials

Research Platform Myelofibrosis and Anemia

NCT069769181 location

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

NCT072506461 location

AlloHCT With PegINFa for Myelofibrosis

NCT055357641 location

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

NCT039645061 location

Therapeutic RSK1 Targeting in Myelofibrosis

NCT073791251 location